Other Titles
Enhancing educator, clinician, and parental competence regarding LGBTQIA+ adolescent health through clinical research and practice
Abstract
Purpose is to assess the prevalence of increased estrone (E1) level as a result of cross-sex estrogen therapy for male to female transgender patients, and compare the levels of conversion of estrogen to estrone from oral, injectable, transdermal, and pellet therapy; female estrone levels should < 33% of total estrogen.
Sigma Membership
Unknown
Lead Author Affiliation
The University of Texas at Austin, Austin, Texas, USA
Type
Presentation
Format Type
Text-based Document
Study Design/Type
N/A
Research Approach
N/A
Keywords:
Breast Cancer, Hormones, Transgender
Recommended Citation
Mijares, Robert Frances, "Retrospective chart review for assessment of risks of estrogen therapy for transgender females" (2019). INRC (Congress). 408.
https://www.sigmarepository.org/inrc/2019/presentations_2019/408
Conference Name
30th International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
Calgary, Alberta, Canada
Conference Year
2019
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Acquisition
Proxy-submission
Retrospective chart review for assessment of risks of estrogen therapy for transgender females
Calgary, Alberta, Canada
Purpose is to assess the prevalence of increased estrone (E1) level as a result of cross-sex estrogen therapy for male to female transgender patients, and compare the levels of conversion of estrogen to estrone from oral, injectable, transdermal, and pellet therapy; female estrone levels should < 33% of total estrogen.
Description
One combined slide deck was submitted for all presentations in this symposium. This slide deck will be attached to at least one other record in the repository. Please look for your preferred session within the combined presentation slides. To locate all records utilizing this slide deck, search by Alternative Title.